Rheumatoid arthritis Trials in Wichita, United States
Conditions / Rheumatoid arthritis / Wichita, United States
Clinical trials for Rheumatoid arthritis investigate a range of treatment strategies and patient populations.
49 total trials for this combination
Showing top 10 of 49 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00443443 | A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE) | COMPLETED | — |
| NCT03915964 | A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis | COMPLETED | PHASE4 |
| NCT01007435 | A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT00891020 | A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs) | COMPLETED | PHASE3 |
| NCT03025308 | Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT01519791 | A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT01194414 | A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT01636817 | A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics | TERMINATED | PHASE2 |
| NCT01215942 | An Open Label Study for Participants With Rheumatoid Arthritis | TERMINATED | PHASE3 |
| NCT00717236 | Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis | COMPLETED | PHASE3 |